Tacrolimus in dermatology - Pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: Part I

SKINmed

Volumn 7, Issue 1, 2008, Pages 27-30

  Sehgal, Virendra N ^a   Srivastava, Govind ^b   Dogra, Sunil ^c  

^a Sehgal Nursing Home   (India)

^b Behl Skin Institute   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

DRUG INTERACTION; HUMAN; REVIEW;

DERMATOLOGIC AGENTS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 38949086012     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: 10.1111/j.1540-9740.2007.06485.x     Document Type: Review

References (46)

1. Contreras Ruiz J, Kerdel FA. Tacrolimus (FK-506) In: Millikan LE, ed. Drug Therapy in Dermatology. 1st ed. New York, NY: Marcel Dekkar, Inc; 2004:161-170.
2. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816-821.
3. Toutous-Trellu L, Abraham S, Pechere M, et al. Topical tacrolimus for effective treatment of eosinophilic folliculitis associated with human immunodeficiency virus infection. Arch Dermatol. 2005;141:1203-1208.
4. Baldo A, Prizio E, Mansueto G, et al. A case of chronic actinic dermatitis treated with topical tacrolimus. J Dermatolog Treat. 2005;16:245-248.
5. Ginarte M, Toribio J. Vulvar lichen sclerosus successfully treated with topical tacrolimus. Eur J Obstet Gynecol Reprod Biol. 2005;123:123-124.
6. Brill TJ, Elshorst-Schmidt T, Valesky EM, et al. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology. 2005;211:351-355.
7. Mackelfresh J, Soon S, Arbiser JL. Combination therapy of doxycycline and topical tacrolimus for venous ulcers. Arch Dermatol. 2005;141:1476-1477.
8. Moreno-Arias GA, Camps-Fresneda A, Llaberia C, et al. Plasma cell balanitis treated with tacrolimus 0.1%. Br J Dermatol. 2005;153:1204-1206.
9. Mitsui T, Kuroda Y, Kunishige M, et al. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005;44:1197-1199.
10. Shichinohe R, Shibaki A, Nishie W, et al. Successful treatment of severe recalcitrant erosive oral lichen planus with topical tacrolimus. J Eur Acad Dermatol Venereol. 2006;20:66-68.
11. Rubegni P, Poggiali S, Sbano P, et al. A case of Darier's disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol. 2006;20:84-87.
12. Rocha Paris F, Fidalgo A, Baptista J, et al. Topical tacrolimus in Hailey-Hailey disease. Int J Tissue React. 2005;27:151-154.
13. Cancer risk with topical pimecrolimus and tacrolimus. Prescrire Int. 2005;14:223.
14. Becker JC, Houben R, Vetter CS, et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: A hypothesis creating case report. BMC Cancer. 2006;6:7.
15. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40:1256-1265.
16. Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987;139:1797-1803.
17. Lawrence ID. Tacrolimus (FK506): Experience in dermatology. Dermatologic Ther. 1998;5:74-84.
18. Beck LA. The efficacy and safety of tacrolimus ointment: A clinical review. J Am Acad Dermatol. 2005;53:S165-S170.
19. Meingassner J, Stütz A. Immunosuppressive macrolides of the type FK506: A novel class of topical agents for treatment of skin diseases? J Invest Dermatol. 1992;98:851-855.
20. Lauerma AI, Stein BD, Homey B, et al. Topical tacrolimus (FK506): percutaneous absorption and effect on allergic and irritant contact dermatitis. J Invest Dermatol. 1993;110:491.
21. Lauerma A, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: Comparison with cyclosporin A. Skin Pharmacol. 1997;10:230-234.
22. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol. 1998;111:396-398.
23. Hooks M. Tacrolimus, a new immunosuppressant: A review of the literature. Ann Pharmacother. 1994;28:501-511.
24. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc. 1991;23:2736-2740.
25. Ruzicka T, Assmann T, Homey B. Tacrolimus: The drug for the turn of the millennium? Arch Dermatol. 1999;135:574-580.
26. Wollenberg A, Regele D, Sharma S, et al. Topical tacrolimus treatment leads to profound alteration of the antigen presenting cells in lesions atopic dermatitis skin. J Invest Dermatol. 1996;107:468.
27. Homey B, Assman T, Vohar HW, et al. Topical FK506 suppress interleukin-12 and costimulatory molecular expression in vivo. J Invest Dermatol. 1997;109:454.
28. Panhans A, Bieber T. FK506 (tacrolimus) impairs the phenotypic and functional differentiation of human epidermal Langerhans cells. J Invest Dermatol. 1996;107:485.
29. de Paulis A, Stellato C, Cirillo R, et al. Antiinflammatory effects of FK506 on human skin mast cells. J Invest Dermatol. 1992;99:723-728
30. Eberlein-Konig B, Ruzicka T, Michel G, et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res. 1997;289:606-608.
31. Griffith JP, Kim JL, Kim EE, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell. 1995;82:507-522.
32. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK 506. Transplant Proc. 1991;23:3105-3108.
33. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136:999-1006.
34. Sand C. Topical tacrolimus ointment may induce skin tags in treated patients. Acta Derm Venereol. 2003;83:317.
35. Bernard LA, Cunningham BB, Al-Suwaidan S, et al. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol. 2003;139:229-231.
36. Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457-460.
37. Fricain JC, Sibaud V, Campana F, et al. Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus. Dermatology. 2005;210:229-232.
38. Siddaiah N, Erickson Q, Miller G, et al. Tacrolimus-induced tinea incognito. Cutis. 2004;73:237-238.
39. Ahn BK, Kim BD, Lee SJ, et al. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol. 2005;52:532-533.
40. Lerbaek A, Agner T. Facial eruption of molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus. Br J Dermatol. 2004;150:1210-1211.
41. Wilson LM, Reid CM. Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment. Australas J Dermatol. 2004;45:184-185.
42. Narang T, Pahwa M, Kanwar JA, et al. Verruca vulgaris following treatment with tacrolimus ointment. Dermatology. 2006;213:254-255.
43. The European FK506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol. 1996;132:419-423
44. Nikolaidis N, Abu-Elmagd K, Thomson AW, et al. Metabolic effects of FK 506 in patient with severe psoriasis: Short-term follow-up of seven cases. Transplant Proc. 1991;23:3325-3327.
45. Kawashima M, Nakagawa H, Ohtsuki M, et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet. 1996;348:1240-1241.
46. Ostovari N, Passeron T, Lacour JP, et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol. 2006;142:252-253.